Please assess the completion status of the following clinical trial:

Trial Title: Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological confirmation of breast carcinoma. Pathologic evidence of dermal lymphatic invasion should be noted but not required.~2. Clinical diagnosis of IBC (presence of inflammatory changes in the involved breast, including diffuse erythema, heat, ridging, and peau d'orange).~3. \>/= Age 18~4. ECOG performance status \</= 1~5. Adequate hematologic function: Absolute neutrophil count (ANC) \>/= 1.5 x 109/L, Platelet count \>/= 100 x 109/L, Hemoglobin \>/= 9.0 g/dL~6. Adequate cardiac function (LVEF \>/= 45%)~7. Adequate Renal function: Creatinine (Cr) \</= 1.5 mg/dL x ULN, Creatinine clearance (CrCl) \>/= 50 mL/min calculated by the Cockcroft-Gault method as follows: Male creatinine clearance = (140 - age) x (weight in Kg) / (serum Cr x 72) Female CrCl = (140 - age) x (weight in Kg) x 0.85 / (serum Cr x 72)~8. Adequate Hepatic function: Aspartate aminotransferase (AST) \</= 2.5 x ULN • Alanine aminotransferase (ALT) \</= 2.5 x ULN • Alkaline phosphatase (Alp) \</= 2.5 x ULN.Total bilirubin \</=1.5 x ULN~9. Ability and willingness to sign an informed consent form for this protocol~10. If female of childbearing potential (women who are post-menopausal \< 1 year, not surgically sterilized, or not abstinent), pregnancy urine test is negative, and agrees to be consistent and correct use of one of the following acceptable methods of birth control: male partner who is sterile prior to the female subject entry into the study and is the sole sexual partner for that female subject; any intrauterine device (IUD) with a documented failure rate of less than 1% per year; oral contraception, or barrier methods, including diaphragm or condom with a spermicide.~11. Patients who have metastatic disease, if the metastatic sites are amendable for local therapy (i.e. radiation and/or surgery), and are candidates for breast surgery will be eligible,~Exclusion Criteria:~1. History of radiation or chemotherapy~2. HER2-positive breast carcinoma (IHC staining more than 3+ or HER2 gene amplification by FISH)~3. Recurrent breast cancer~4. History of other malignancies (except for cured non-melanomatous skin cancer or cured cervical carcinoma in situ, or malignancies with no evidence of disease and no treatment for \>5 years)~5. Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection~6. History of extensive interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or any evidence of extensive interstitial lung disease on baseline chest CT scan~7. Patient with other significant medical or psychiatric condition that would make assessment of toxicity or efficacy difficult.~8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~9. Peripheral neuropathy \>= Gr II

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PNC + FEC (Type: EXPERIMENTAL): PNC = Panitumumab + Nab-paclitaxel + Carboplatin, and~FEC = 5-fluorouracil, epirubicin, and cyclophosphamide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete